![](https://cdn.sanity.io/images/0vv8moc6/pharmtech/2b6495cc1c9eda73b83dc43c7e3fb48e6cf84ea8-1280x720.jpg?fit=crop&auto=format)
AdvanCell Completes $112 Million Oversubscribed Series C Financing
AdvanCell, a Sydney, Australia-based, clinical-stage radiopharmaceutical company founded in 2019 that specializes in the development of cancer therapeutics, has successfully completed an oversubscribed, $112 million round of Series C financing (1). The …